Current Report Filing (8-k)
January 09 2017 - 5:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
January 9, 2017
Date of Report (Date of earliest event reported)
JAZZ
PHARMACEUTICALS PUBLIC LIMITED COMPANY
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Ireland
|
|
001-33500
|
|
98-1032470
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
Fourth Floor, Connaught House
1 Burlington Road, Dublin 4, Ireland
(Address of principal executive offices, including zip code)
011-353-1-634-7800
(Registrants telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c))
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On January 9, 2017, at the J.P. Morgan Healthcare
Conference in San Francisco, California, Jazz Pharmaceuticals plc (the Company) presented a corporate overview and financial update, which presentation included the Companys current expectations with respect to certain operating
results for the year ended December 31, 2016. The presentation was announced by a widely disseminated press release and was made available to the public by audio webcast, and the slides that accompanied the presentation were made available to
the public on the Companys website. A transcript of the relevant portion of the presentation relating to the aforementioned financial update is attached hereto as Exhibit 99.1, along with a copy of the relevant slides containing such
information.
The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 to this Current Report on Form
8-K
shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2)
of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 to this Current Report on Form
8-K
shall not be incorporated by reference into any
filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
Exhibits
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Portion of transcript and related slides of presentation by Jazz Pharmaceuticals plc on January 9, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
|
|
|
By:
|
|
/s/ Matthew P. Young
|
|
|
Matthew P. Young
|
|
|
Executive Vice President and Chief Financial Officer
|
Date: January 9, 2017
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Portion of transcript and related slides of presentation by Jazz Pharmaceuticals plc on January 9, 2017
|
Jazz Pharmaceuticals (NASDAQ:JAZZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Jazz Pharmaceuticals (NASDAQ:JAZZ)
Historical Stock Chart
From Sep 2023 to Sep 2024